



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BRM/BRG1 ATP Inhibitor 1

Item No. 36138

CAS Registry No.: 2270879-17-7
Formal Name: N-[3-(difluoromethyl)-5-isothiazolyl]-N'-[2-fluoro-5-(hydroxymethyl)-4-pyridinyl]-urea
Synonym: Brahma Homologue/Brahma-related Gene 1 Adenosine 5'-triphosphate Inhibitor 1
MF: C₁₁H₉F₃N₄O₂S
FW: 318.3
Purity: ≥98%
UV/Vis.: λ_{max}: 276 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BRM/BRG1 ATP inhibitor 1 is supplied as a solid. A stock solution may be made by dissolving the BRM/BRG1 ATP inhibitor 1 in the solvent of choice, which should be purged with an inert gas. BRM/BRG1 ATP inhibitor 1 is soluble in DMSO.

Description

BRM/BRG1 ATP inhibitor 1 is an allosteric dual inhibitor of brahma homologue (BRM), also known as SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 2 (SMARCA2), and brahma-related gene 1 (BRG1), also known as SMARCA4, ATPase activities (IC₅₀s = <0.005 μM for both).¹ It reduces the expression of keratin 80 (KRT80) in H1299 and RERF-LC-A1 cells. BRM (20mg/kg) reduces tumor growth in a RERF-LC-A1 lung cancer mouse xenograft model.

Reference

1. Papillon, J.P.N., Nakajima, K., Adair, C.D., *et al.* Discovery of orally active inhibitors of brahma homologue (BRM)/SMARCA2 ATPase activity for the treatment of brahma related gene 1 (BRG1)/SMARCA4-mutant cancers. *J. Med. Chem.* **61**(22), 10155-10172 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM